Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JWCAR239 in R/R B-NHL
NCT07024147Phase 1Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JWCAR239 in B-cell non-Hodgkin lymphoma, sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Rate of Dose Limiting Toxicity events at 28 days and Adverse Event and Serious Adverse Event rate at 2 years. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
JWCAR239
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07024147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024147.